Novan

Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Its products pipeline includes SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Durham, NC.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novan develops products that tap the anti-bacterial properties of nitric oxide by encapsulating the compound in nano-particles that deliver therapeutic agents to desired body location. They use its proprietary nitric oxide-based science and technology platform to develop innovative, first-in-class therapies for unmet medical needs. The company is committed to using the power of the human body to create safe and effective treatments. They complement their internal scientific talent with strategic partners around the globe to enable Novan to harness the power of nitric oxide and develop technologies that will help address currently untreated and under-treated medical conditions. It was incorporated in 2008 and is based in Morrisville, North Carolina.

As weight-loss treatments dominate the pharmaceutical market, Swiss drugmaker Novartis AG (SWX: NOVN) is choosing a different path. While competitors like Eli Lilly and Novo Nordisk race to capture the booming weight-loss drug market, Novartis is steering clear of the frenzy.

How Novartis plans to thrive without competing directly with Eli Lilly in weight loss drug market

– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan's assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing –

Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection

DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company's 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6, 2023 at 9:30 a.m. Eastern Time in a virtual format.

Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders

– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum –

Novan Focuses Strategic Direction and Announces Restructuring

Novan, Inc. (NASDAQ:NOVN ) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President & Chief Executive Officer John Donofrio - Executive Vice President & Chief Operating Officer John Gay - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Jeff Jones - Oppenheimer Jonathan Aschoff - Roth Capital Kemp Dolliver - Brookline Capital Markets John Vandermosten - Zacks Operator Hello and welcome to the Novan Inc. Quarterly Update Conference Call and Webcast.

Novan, Inc. (NOVN) Q1 2023 Earnings Call Transcript

– Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong prescription growth across three promoted products – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C.

Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update

DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

Novan to Report First Quarter 2023 Financial Results on May 15, 2023

Published results from a National Psoriasis Foundation-fielded survey included responses from more than 400 patients across US 1

Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹

Live moderated webcast with members of the Novan management team and dermatological key opinion leader, Dr. Jeffrey Sugarman on Tuesday, April 25th at 2:00 PM ET Live moderated webcast with members of the Novan management team and dermatological key opinion leader, Dr. Jeffrey Sugarman on Tuesday, April 25th at 2:00 PM ET

Novan to Host Analyst and Investor Event: A Discussion of Molluscum's Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD

Novan Inc. (NASDAQ:NOVN ) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Paula Brown Stafford - President, Chief Executive Officer John Donofrio - Executive Vice President, Chief Operating Officer John Gay - Chief Financial Officer Conference Call Participants Jonathan Aschoff - Roth Capital Oren Livnat - HC Wainwright Jeff Jones - Oppenheimer Jennifer Kim - Cantor Fitzgerald Kemp Dolliver - Brookline Capital Markets John Vandermosten - Zacks Operator Hello and welcome to the Novan Inc. full year 2022 update conference call and webcast. As a brief reminder, all participants are currently in a listen-only mode.

Novan (NOVN) Q4 2022 Earnings Call Transcript

– Berdazimer gel, 10.3% (SB206) assigned PDUFA goal date of January 5, 2024 –

Novan Reports Full Year 2022 Financial Results and Provides Corporate Update

DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2022 financial results on Thursday, March 30th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

Novan to Report Full Year 2022 Financial Results on March 30, 2023

DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the issuance and sale in the Company's previously announced registered direct offering of an aggregate of (i) 5,042,017 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and (ii) warrants (the “Common Warrants”) to purchase up to 5,042,017 shares of common stock, at an effective combined purchase price of $1.19 per share (or pre-funded warrant) and associated Common Warrant. The Common Warrants will become exercisable six months from the date of issuance at an exercise price of $1.20 per share and will expire five years following the initial exercise date.

Novan Announces Closing of $6.0 Million Registered Direct Offering

Presentation with live webcast today, March 14th at 10:40 AM ET Presentation with live webcast today, March 14th at 10:40 AM ET

Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference

DURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has entered into definitive agreements for the issuance and sale in a registered direct offering of an aggregate of (i) 5,042,017 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and (ii) warrants (the “Common Warrants”) to purchase up to 5,042,017 shares of common stock, at an effective combined purchase price of $1.19 per share (or pre-funded warrant) and associated Common Warrant. The Common Warrants will become exercisable six months from the date of issuance at an exercise price of $1.20 per share and will expire five years following the initial exercise date.

Novan Announces $6.0 Million Registered Direct Offering

– Novan is a fully integrated pharmaceutical company with proven capabilities across drug development through to commercialization –

Novan Moves Forward with Unified Corporate Branding

– FDA completes filing review of application with no filing issues identified –

FDA Accepts Novan's NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024

Live video webcast on Thursday, January 19th at 12:00 PM ET Live video webcast on Thursday, January 19th at 12:00 PM ET

Novan to Present at the Virtual Investor 2023 Companies to Watch Event

Ligand Pharmaceuticals

SAN DIEGO--( BUSINESS WIRE )--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Novan, Inc. (Nasdaq: NOVN) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum (molluscum). Assuming the filing is accepted by the FDA and given a typical 12-month review process, Novan anticipates a potential first quarter 2024 approval.

Ligand's Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines –

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of Novan, has entered into an exclusive license agreement with Sato Pharmaceutical Co., Ltd. (“Sato”) granting Sato the right to develop, manufacture and market RHOFADE® (oxymetazoline hydrochloride 1% cream) for rosacea in Japan.

EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in Japan

– Agreement provides immediate access to cash flow –

EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement

– Paula Brown Stafford, President and Chief Executive Officer of Novan to participate in a live moderated panel discussion on Thursday, December 8th at 11:00 AM ET –

Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference

Novan, Inc. (NASDAQ:NOVN ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President, and Chief Executive Officer John Gay - Chief Financial Officer John Donofrio - Chief Operating Officer and President, EPI Health Conference Call Participants Jeff Jones - Oppenheimer Jennifer Kim - Cantor Fitzgerald Kemp Dolliver - Brookline Capital Markets John Vandermosten - Zacks Operator Hello, and welcome to the Novan, Inc. Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

Novan, Inc. (NOVN) Q3 2022 Earnings Call Transcript

– Rhofade prescriptions increased 37% for third quarter year-to-date from prior year –

News for Novan Stock (NOVN)